Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 2, 2026, 9:27 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 49–72 of 609 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Interstitial Lung Diseases Clear all
Recruiting Phase 2 Interventional

Efficacy of Two Doses of Duloxetine & Amitriptyline in Interstitial Lung Disease-related Cough

NCT05120934
View directory record Official record
Conditions
Interstitial Lung Disease
Interventions
Amitriptyline 25 MG, Amitriptyline 50 MG, Duloxetine 30 MG, Duloxetine 60 MG, Placebo 30 MG, Placebo 60 MG
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 75 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jan 21, 2026 · Synced Oct 2, 2026, 9:27 PM EDT
Not listed Phase 1Phase 2 Interventional

CD34+ (Malignant) Stem Cell Selection for Patients Receiving Allogenic Stem Cell Transplant

NCT02061800
View directory record Official record
Conditions
Chronic Myeloid Leukemia (CML), Acute Myelogenous Leukemia (AML), Myelodysplastic Syndrome (MDS), Juvenile Myelomonocytic Leukemia (JMML), Acute Lymphoblastic Leukemia (ALL), Lymphoma (Hodgkin's and Non-Hodgkin's)
Interventions
CliniMACS CD34+ Reagent System, Thiotepa, Cyclophosphamide, Alemtuzumab, Tacrolimus, Melphalan, Busulfan, Fludarabine, Methylprednisolone
Device · Drug
Lead sponsor
Diane George
Other
Eligibility
Up to 22 Years
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2026
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 4, 2024 · Synced Oct 2, 2026, 9:27 PM EDT
Withdrawn No phase listed Observational

Natural History of Granulomatosis With Polyangiitis: Clinical and Genetic Biomarkers of Airway Disease NoAAC PR-03 Study

NCT03182049
View directory record Official record
Conditions
Granulomatosis With Polyangiitis
Interventions
Airway assessment, Rheumatology assessment
Procedure
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Aug 25, 2020 · Synced Oct 2, 2026, 9:27 PM EDT
Completed Phase 3 Interventional

Abatacept for the Treatment of Relapsing, Non-Severe, Granulomatosis With Polyangiitis (Wegener's)

NCT02108860
View directory record Official record
Conditions
Granulomatosis With Polyangiitis (Wegener's), Granulomatosis With Polyangiitis, Wegener's Granulomatosis, ANCA-Associated Vasculitis
Interventions
Abatacept, placebo
Drug
Lead sponsor
University of South Florida
Other
Eligibility
15 Years and older
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2023
U.S. locations
10
States / cities
Los Angeles, California • Tampa, Florida • Kansas City, Kansas + 7 more
Source: ClinicalTrials.gov public record
Updated Jul 29, 2024 · Synced Oct 2, 2026, 9:27 PM EDT
Active, not recruiting No phase listed Observational Accepts healthy volunteers

Advancing Prevention of Pulmonary Fibrosis

NCT04564183
View directory record Official record
Conditions
IPF, Pulmonary Fibrosis, ILD
Interventions
Sample collection, Questionnaires, High resolution CT scan of the chest, Pulmonary Function Test
Other · Radiation · Diagnostic Test
Lead sponsor
University of Colorado, Denver
Other
Eligibility
40 Years to 75 Years
Enrollment
800 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2026
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Mar 25, 2025 · Synced Oct 2, 2026, 9:27 PM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

Detection of Integrin avb6 in IPF, PSC, and COVID19 Using PET/CT

NCT03183570
View directory record Official record
Conditions
Idiopathic Pulmonary Fibrosis, Primary Sclerosing Cholangitis, Covid19 Pneumonia
Interventions
[18F]FP-R01-MG-F2
Drug
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2025
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Feb 4, 2025 · Synced Oct 2, 2026, 9:27 PM EDT
Completed No phase listed Observational

ILAs in CT Lung Cancer Screening Population

NCT04503044
View directory record Official record
Conditions
Interstitial Lung Disease, IPF
Interventions
Retrospective observational study
Other
Lead sponsor
Lahey Clinic
Other
Eligibility
18 Years to 80 Years
Enrollment
1,703 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021
U.S. locations
1
States / cities
Burlington, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 3, 2021 · Synced Oct 2, 2026, 9:27 PM EDT
Terminated Phase 3 Interventional

The INSPIRE Trial: A Study of Interferon Gamma-1b for Idiopathic Pulmonary Fibrosis (IPF)

NCT00075998
View directory record Official record
Conditions
Idiopathic Pulmonary Fibrosis, Lung Disease, Pulmonary Fibrosis
Interventions
Interferon gamma-1b ("Actimmune")
Drug
Lead sponsor
InterMune
Industry
Eligibility
40 Years to 79 Years
Enrollment
826 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2007
U.S. locations
1
States / cities
Brisbane, California
Source: ClinicalTrials.gov public record
Updated Jul 2, 2009 · Synced Oct 2, 2026, 9:27 PM EDT
Recruiting No phase listed Observational

Clinical and Basic Investigations Into Hermansky-Pudlak Syndrome

NCT00001456
View directory record Official record
Conditions
Hermansky-Pudlak Syndrome (HPS)
Interventions
Not listed
Lead sponsor
National Human Genome Research Institute (NHGRI)
NIH
Eligibility
1 Month to 115 Years
Enrollment
600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1995
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 9, 2026 · Synced Oct 2, 2026, 9:27 PM EDT
Completed No phase listed Observational

Immune Response in Hypersensitivity Pneumonitis

NCT03873649
View directory record Official record
Conditions
Hypersensitivity Pneumonitis
Interventions
Bronchoscopy with lavage
Other
Lead sponsor
Nabeel Hamzeh
Other
Eligibility
18 Years to 80 Years
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
1
States / cities
Iowa City, Iowa
Source: ClinicalTrials.gov public record
Updated May 18, 2022 · Synced Oct 2, 2026, 9:27 PM EDT
Not yet recruiting Phase 3 Interventional

Long-term Extension Study to Evaluate Safety and Tolerability of Admilparant in Participants With Pulmonary Fibrosis

NCT07441408
View directory record Official record
Conditions
Pulmonary Fibrosis
Interventions
BMS-986278
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
Not listed
Enrollment
2,380 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
3
States / cities
Birmingham, Alabama • Ocala, Florida • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 14, 2026 · Synced Oct 2, 2026, 9:27 PM EDT
Completed No phase listed Observational

Pulmonary Hypertension Screening in Patients With Interstitial Lung Disease for Earlier Detection

NCT05776225
View directory record Official record
Conditions
Interstitial Lung Disease, Pulmonary Hypertension
Interventions
Right heart catheterization (RHC)
Procedure
Lead sponsor
United Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
314 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
42
States / cities
Phoenix, Arizona • Hartford, Connecticut • Lakeland, Florida + 38 more
Source: ClinicalTrials.gov public record
Updated May 28, 2026 · Synced Oct 2, 2026, 9:27 PM EDT
Completed Phase 1 Interventional

A Study of Oral Vismodegib in Combination With Pirfenidone in Participants With Idiopathic Pulmonary Fibrosis

NCT02648048
View directory record Official record
Conditions
Idiopathic Pulmonary Fibrosis
Interventions
Pirfenidone, Vismodegib
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
40 Years to 80 Years
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016
U.S. locations
14
States / cities
La Jolla, California • Orlando, Florida • Elk Grove, Illinois + 11 more
Source: ClinicalTrials.gov public record
Updated Oct 30, 2017 · Synced Oct 2, 2026, 9:27 PM EDT
Terminated Phase 2 Interventional Results available

Study to Assess the Efficacy and Safety of Simtuzumab (GS-6624) in Adults With Idiopathic Pulmonary Fibrosis (IPF)

NCT01769196
View directory record Official record
Conditions
Idiopathic Pulmonary Fibrosis
Interventions
Simtuzumab, Simtuzumab placebo
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
45 Years to 85 Years
Enrollment
544 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
72
States / cities
Birmingham, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 55 more
Source: ClinicalTrials.gov public record
Updated May 30, 2017 · Synced Oct 2, 2026, 9:27 PM EDT
Completed Not applicable Interventional Results available

Project to Improve Communication About Serious Illness--Hospital Study: Pragmatic Trial (Trial 1)

NCT04281784
View directory record Official record
Conditions
Dementia, Chronic Disease, Neoplasm Metastasis, Lung Neoplasm, Pulmonary Disease, Chronic Obstructive, Heart Failure，Congestive, Liver Cirrhosis, Kidney Failure, Chronic, Lung Diseases, Interstitial, Peripheral Vascular Disease, Diabetes With End Organ Injury
Interventions
EHR-based Clinician Jumpstart
Behavioral
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older
Enrollment
2,512 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
3
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Apr 4, 2025 · Synced Oct 2, 2026, 9:27 PM EDT
Completed Phase 2 Interventional

Aerobic Exercise in Patients With Pulmonary Hypertension

NCT00678821
View directory record Official record
Conditions
Pulmonary Hypertension, Interstitial Lung Disease
Interventions
Aerobic exercise
Other
Lead sponsor
National Institutes of Health Clinical Center (CC)
NIH
Eligibility
21 Years to 82 Years
Enrollment
97 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2015
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 28, 2026 · Synced Oct 2, 2026, 9:27 PM EDT
Completed No phase listed Observational

MRI for Screening and Monitoring Scleroderma ILD

NCT05204355
View directory record Official record
Conditions
Scleroderma
Interventions
MRI, Hyperpolarized Xe129, HRCT
Diagnostic Test · Drug
Lead sponsor
University of Kansas Medical Center
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
1
States / cities
Kansas City, Kansas
Source: ClinicalTrials.gov public record
Updated May 1, 2026 · Synced Oct 2, 2026, 9:27 PM EDT
Completed Phase 2 Interventional Results available

Phase 2a Evaluation of PLN-74809 on αvβ6 Receptor Occupancy Using PET Imaging in Participants With IPF/

NCT04072315
View directory record Official record
Conditions
Idiopathic Pulmonary Fibrosis
Interventions
PLN-74809, Knottin tracer
Drug · Radiation
Lead sponsor
Pliant Therapeutics, Inc.
Industry
Eligibility
40 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated Dec 12, 2023 · Synced Oct 2, 2026, 9:27 PM EDT
Enrolling by invitation No phase listed Observational Accepts healthy volunteers

University of Virginia Natural History Study

NCT04896138
View directory record Official record
Conditions
Interstitial Lung Disease, Idiopathic Pulmonary Fibrosis, Sarcoidosis, Connective Tissue Diseases, Hypersensitivity Pneumonitis, Idiopathic Interstitial Pneumonias
Interventions
Interstitial Lung Disease
Other
Lead sponsor
University of Virginia
Other
Eligibility
18 Years and older
Enrollment
2,500 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2035
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated May 8, 2024 · Synced Oct 2, 2026, 9:27 PM EDT
Terminated Phase 3 Interventional

A Study With Imlifidase in Anti-GBM Disease

NCT05679401
View directory record Official record
Conditions
Anti-Glomerular Basement Membrane Disease, Anti-Glomerular Basement Membrane Antibody Disease, Goodpasture Syndrome, Good Pasture Syndrome
Interventions
Imlifidase, Plasma exchange (PLEX), Cyclophosphamide (CYC), Glucocorticoids
Drug · Procedure
Lead sponsor
Hansa Biopharma AB
Industry
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
6
States / cities
Los Angeles, California • Baltimore, Maryland • Boston, Massachusetts + 3 more
Source: ClinicalTrials.gov public record
Updated Mar 4, 2026 · Synced Oct 2, 2026, 9:27 PM EDT
Completed Phase 2 Interventional

Etanercept to Treat Wegener's Granulomatosis

NCT00001901
View directory record Official record
Conditions
Vasculitis, Wegener's Granulomatosis
Interventions
Etanercept
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
Not listed
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2005
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 4, 2008 · Synced Oct 2, 2026, 9:27 PM EDT
Completed Not applicable Interventional

The Six Minute Walk Test: Influence of Instruction on Results

NCT01789996
View directory record Official record
Conditions
Interstitial Lung Disease
Interventions
alternative six minute walk test, Standard six minute walk test
Procedure
Lead sponsor
Inova Health Care Services
Other
Eligibility
18 Years to 90 Years
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
1
States / cities
Falls Church, Virginia
Source: ClinicalTrials.gov public record
Updated Jun 16, 2020 · Synced Oct 2, 2026, 9:27 PM EDT
Recruiting Phase 2 Interventional

Pulmonary Hypertension SOLAR

NCT04778046
View directory record Official record
Conditions
Interstitial Lung Disease, COPD, Pulmonary Arterial Hypertension
Interventions
Hyperpolarized 129Xe
Drug
Lead sponsor
Bastiaan Driehuys
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Feb 24, 2026 · Synced Oct 2, 2026, 9:27 PM EDT
Withdrawn Phase 4 Interventional

Pulmonary Arterial Hypertension Secondary to Idiopathic Pulmonary Fibrosis and Treatment With Bosentan

NCT00625469
View directory record Official record
Conditions
Pulmonary Arterial Hypertension, Idiopathic Pulmonary Fibrosis
Interventions
bosentan
Drug
Lead sponsor
Rajan Saggar
Other
Eligibility
Not listed
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
2
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Mar 6, 2018 · Synced Oct 2, 2026, 9:27 PM EDT